Health Score

0 Good

Metadata coverage

Abstract

ORCID

References

License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder

Award / grant

Affiliation & institutional identifiers

Affiliation

ROR ID

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

Attach ORCID iDs across 4600 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

High impact4600 DOIs

Add abstracts to 1031 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

Low impact1031 DOIs

Deposit reference lists for 872 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact872 DOIs

DOIs for this ISSN

Showing the top 5 of 7637 DOIs, ordered by correction priority.

#	Title	Missing	Priority	Citations
1	Circulating microRNA in body fluid: a new potential biomarke… (10.1111/j.1349-7006.2010.01650.x)	ORCID	76.30	1126
2	Oncolytic virus therapy: A new era of cancer treatment at da… (10.1111/cas.13027)	ORCID	70.92	686
3	Bystander killing effect of <scp>DS</scp>‐8201a, a novel ant… (10.1111/cas.12966)	ORCID	70.81	679
4	Metabolic activation of polycyclic aromatic hydrocarbons to… (10.1111/j.1349-7006.2004.tb03162.x)	ORCID	70.39	653
5	Signaling networks guiding epithelial–mesenchymal transition… (10.1111/j.1349-7006.2007.00550.x)	ORCID	70.14	638
6	Epithelial–mesenchymal transition in cancer development and… (10.1111/j.1349-7006.2009.01419.x)	ORCID	69.63	609
7	A novel inflammation‐related mouse colon carcinogenesis mode… (10.1111/j.1349-7006.2003.tb01386.x)	ORCID	69.53	603
8	Heterocyclic amines: Mutagens/carcinogens produced during co… (10.1111/j.1349-7006.2004.tb03205.x)	ORCID	68.70	559
9	Role of BRCA1 and BRCA2 as regulators of DNA repair, transcr… (10.1111/j.1349-7006.2004.tb02195.x)	ORCID	68.61	554
10	Regulation of cancer cell motility through actin reorganizat… (10.1111/j.1349-7006.2005.00062.x)	ORCID	67.47	499
11	Mutations of the epidermal growth factor receptor gene and r… (10.1111/j.1349-7006.2007.00607.x)	ORCID	67.28	490
12	Reduced expression of <i>Dicer</i> associated with poor prog… (10.1111/j.1349-7006.2005.00015.x)	ORCID	67.23	488
13	Carbohydrate‐mediated cell adhesion in cancer metastasis and… (10.1111/j.1349-7006.2004.tb03219.x)	ORCID	67.08	481
14	Clinical significance of macrophage heterogeneity in human m… (10.1111/cas.12314)	ORCID	66.99	477
15	Tumor‐derived spheroids: Relevance to cancer stem cells and… (10.1111/cas.13155)	ORCID	66.73	466
16	Role of iron in carcinogenesis: Cancer as a ferrotoxic disea… (10.1111/j.1349-7006.2008.01001.x)	ORCID	66.66	463
17	Cancer/testis (CT) antigens: Potential targets for immunothe… (10.1111/j.1349-7006.2009.01303.x)	ORCID	66.38	451
18	Preclinical and clinical studies of anticancer agent‐incorpo… (10.1111/j.1349-7006.2009.01103.x)	ORCID	66.35	450
19	ADAMs in cancer cell proliferation and progression (10.1111/j.1349-7006.2007.00434.x)	ORCID	66.31	448
20	YN968D1 is a novel and selective inhibitor of vascular endot… (10.1111/j.1349-7006.2011.01939.x)	ORCID	65.45	414
21	Molecular targeting therapy of cancer: drug resistance, apop… (10.1111/j.1349-7006.2003.tb01345.x)	ORCID	65.35	410
22	Basic mechanisms of high‐risk human papillomavirus‐induced c… (10.1111/j.1349-7006.2007.00546.x)	ORCID	64.72	387
23	Functional roles of <i>N</i>‐glycans in cell signaling and c… (10.1111/j.1349-7006.2008.00839.x)	ORCID	64.44	377
24	Epidemiology of cholangiocarcinoma: An update focusing on ri… (10.1111/j.1349-7006.2009.01458.x)	ORCID	64.21	369
25	Not all epidermal growth factor receptor mutations in lung c… (10.1111/cas.12996)	ORCID	63.82	356
26	Cell adhesion system and human cancer morphogenesis (10.1111/j.1349-7006.2003.tb01485.x)	ORCID	63.73	353
27	Genetic alterations and signaling pathways in the evolution… (10.1111/j.1349-7006.2009.01308.x)	ORCID	63.06	332
28	Aminopeptidase N (CD13) as a target for cancer chemotherapy (10.1111/j.1349-7006.2010.01826.x)	ORCID	62.63	319
29	Novel combination of serum microRNA for detecting breast can… (10.1111/cas.12880)	ORCID	62.35	311
30	Mechanism and biological significance of CD44 cleavage (10.1111/j.1349-7006.2004.tb03179.x)	ORCID	62.28	309
31	The ALK‐5 inhibitor A‐83‐01 inhibits Smad signaling and epit… (10.1111/j.1349-7006.2005.00103.x)	ORCID	62.07	303
32	Detailed characterization of the mouse glioma 261 tumor mode… (10.1111/j.1349-7006.2006.00208.x)	ORCID	62.07	303
33	Tumor hypoxia: A target for selective cancer therapy (10.1111/j.1349-7006.2003.tb01395.x)	ORCID	62.04	302
34	Nectins and nectin‐like molecules: Roles in cell adhesion, m… (10.1111/j.1349-7006.2003.tb01499.x)	ORCID	61.86	297
35	Understanding and exploiting <i>hTERT</i> promoter regulatio… (10.1111/j.1349-7006.2008.00878.x)	ORCID	61.67	292
36	Intracellular zinc homeostasis and zinc signaling (10.1111/j.1349-7006.2008.00854.x)	ORCID	61.48	287
37	Diagnostic performance of computer tomography, magnetic reso… (10.1111/j.1349-7006.2010.01532.x)	ORCID	61.14	278
38	Overexpression of yes‐associated protein contributes to prog… (10.1111/j.1349-7006.2010.01511.x)	ORCID	61.02	275
39	Molecular links between tumor angiogenesis and inflammation:… (10.1111/j.1349-7006.2008.00853.x)	ORCID	60.90	272
40	Targeting <scp>DNA</scp> damage response in cancer therapy (10.1111/cas.12366)	ORCID	60.50	262
41	Signal transduction of inflammatory cytokines and tumor deve… (10.1111/j.1349-7006.2006.00197.x)	ORCID	60.25	256
42	Molecular analysis of the pathophysiological binding of the… (10.1111/j.1349-7006.2007.00634.x)	ORCID	60.16	254
43	Cancer‐associated fibroblast and <scp>M</scp>2 macrophage ma… (10.1111/cas.12096)	ORCID	60.12	253
44	Salt, salted food intake, and risk of gastric cancer: Epidem… (10.1111/j.1349-7006.2005.00006.x)	ORCID	60.08	252
45	<scp>l</scp>‐Type amino acid transporter 1 inhibitors inhibi… (10.1111/j.1349-7006.2009.01386.x)	ORCID	59.90	248
46	Head and neck cancer in the betel quid chewing area: recent… (10.1111/j.1349-7006.2008.00863.x)	ORCID	59.82	246
47	<i>IDH</i> mutations predict longer survival and response to… (10.1111/j.1349-7006.2011.02134.x)	ORCID	59.77	245
48	Loss of 5‐hydroxymethylcytosine is accompanied with malignan… (10.1111/j.1349-7006.2012.02213.x)	ORCID	59.77	245
49	Significance of alternatively activated macrophages in patie… (10.1111/j.1349-7006.2010.01614.x)	ORCID	59.60	241
50	Molecular functions and biological roles of hepatitis B viru… (10.1111/j.1349-7006.2006.00299.x)	ORCID	59.46	238